Appleby Paul, Beral Valerie, Berrington de González Amy, Colin Didier, Franceschi Silvia, Goodhill Adrian, Green Jane, Peto Julian, Plummer Martyn, Sweetland Siân
Cancer Research UK Epidemiology Unit, Oxford, UK.
Lancet. 2007 Nov 10;370(9599):1609-21. doi: 10.1016/S0140-6736(07)61684-5.
Combined oral contraceptives are classified by the International Agency for Research on Cancer as a cause of cervical cancer. As the incidence of cervical cancer increases with age, the public-health implications of this association depend largely on the persistence of effects long after use of oral contraceptives has ceased. Information from 24 studies worldwide is pooled here to investigate the association between cervical carcinoma and pattern of oral contraceptive use.
Individual data for 16,573 women with cervical cancer and 35,509 without cervical cancer were reanalysed centrally. Relative risks of cervical cancer were estimated by conditional logistic regression, stratifying by study, age, number of sexual partners, age at first intercourse, parity, smoking, and screening.
Among current users of oral contraceptives the risk of invasive cervical cancer increased with increasing duration of use (relative risk for 5 or more years' use versus never use, 1.90 [95% CI 1.69-2.13]). The risk declined after use ceased, and by 10 or more years had returned to that of never users. A similar pattern of risk was seen both for invasive and in-situ cancer, and in women who tested positive for high-risk human papillomavirus. Relative risk did not vary substantially between women with different characteristics.
The relative risk of cervical cancer is increased in current users of oral contraceptives and declines after use ceases. 10 years' use of oral contraceptives from around age 20 to 30 years is estimated to increase the cumulative incidence of invasive cervical cancer by age 50 from 7.3 to 8.3 per 1000 in less developed countries and from 3.8 to 4.5 per 1000 in more developed countries.
国际癌症研究机构将复方口服避孕药列为宫颈癌的一个致病因素。由于宫颈癌的发病率随年龄增长而上升,这种关联对公共卫生的影响在很大程度上取决于口服避孕药停用后很长时间内影响的持续性。本文汇总了来自全球24项研究的信息,以调查宫颈癌与口服避孕药使用模式之间的关联。
对16573例宫颈癌女性和35509例无宫颈癌女性的个体数据进行集中重新分析。通过条件逻辑回归估计宫颈癌的相对风险,并按研究、年龄、性伴侣数量、首次性交年龄、生育次数、吸烟情况和筛查情况进行分层。
在当前口服避孕药使用者中,浸润性宫颈癌的风险随着使用时间的延长而增加(使用5年或更长时间与从未使用者相比,相对风险为1.90[95%CI 1.69 - 2.13])。停用后风险下降,到10年或更长时间后已恢复到从未使用者的水平。浸润性癌和原位癌以及高危人乳头瘤病毒检测呈阳性的女性中均观察到类似的风险模式。不同特征女性之间的相对风险没有显著差异。
当前口服避孕药使用者患宫颈癌的相对风险增加,停用后风险下降。估计在20岁至30岁左右使用10年口服避孕药,在欠发达国家会使50岁时浸润性宫颈癌的累积发病率从每1000人7.3例增加到8.3例,在发达国家则从每1000人3.8例增加到4.5例。